Medicine measures the body objectively
Heart rhythm. Blood pressure. Oxygen saturation. Glucose. Imaging. Biomarkers.
Company
Making brain performance measurable
RetinaTek was founded to make objective, repeatable cognitive measurement practical, beginning with the unmet need for longitudinal measurement across concussion recovery.
Healthcare measures the heart, lungs, and metabolism with objective tools. Cognitive function still often depends on subjective reports, brief screens, or lengthy specialist evaluations. RetinaTek is building the measurement layer for brain performance: fast, repeatable, task-evoked, and grounded in federally funded neuroscience.
Closing the cognitive measurement gap
Cognitive function affects readiness, recovery, treatment response, independence, safety, and quality of life. Yet practical tools for measuring cognitive performance over time remain limited.
RetinaTek exists to make brain-performance measurement objective, repeatable, and interpretable. The company's platform, RETINA, uses task-evoked eye tracking, pupil dynamics, manual responses, and stimulus timing to measure cognitive performance under controlled cognitive load.
Cognition is still often measured indirectly
Self-report. Symptom checklists. Brief screens. Long specialist evaluations. Episodic visits.
RetinaTek is building the missing measurement layer
Objective, repeatable cognitive-performance measurement designed for real-world deployment.
From military neuroscience to scalable measurement
RETINA was shaped in demanding military and clinical research environments, where objective measurement of cognitive performance, injury effects, and recovery trajectory has been studied. RetinaTek was formed to bring that measurement capability into broader healthcare, research, and performance settings.
Scientific origin
The technology began with clinical neuropsychology research focused on eye movements, reaction time, inhibition, attention, and cognitive control.
Military validation
The approach was developed and validated in military and clinical research settings where objective assessment of TBI, cognitive performance, and recovery trajectory was urgently studied.
Evidence base
Peer-reviewed studies established support across attention, cognitive load, performance validity, military TBI, pupillometry, and MRI-linked biology.
Commercialization
RetinaTek was formed to move RETINA from federally funded research systems into scalable products, beginning with paid research and sponsored pilots, then a staged path from RT-Focus to condition-specific RT-TRACE development.
Born in military neuroscience. Built for broader clinical, research, and performance applications.
Built by science and commercialization working together
RetinaTek pairs the lead inventor of the measurement science with an operator focused on turning validated research into a scalable company.
Mark L. Ettenhofer, PhD
Clinical neuropsychologist, lead inventor of the core RETINA technology, and principal architect of the scientific program behind task-evoked neurocognitive measurement. Dr. Ettenhofer has spent his career developing objective tools for assessing attention, cognitive control, brain injury effects, and recovery in military and clinical research settings.
- Lead inventor (with D. Barry) of the core RETINA technology
- Clinical neuropsychologist
- Federally funded military and clinical research background
- Peer-reviewed work across attention, TBI, cognitive load, pupillometry, performance validity, and MRI-linked biology
Ben Bulloch
Commercialization operator responsible for RetinaTek's financing, partnerships, operations, product strategy, regulatory strategy, and market development. Ben's role is to move validated science into scalable products, paid deployments, and venture-scale clinical and commercial markets.
- Financing and capital strategy
- Strategic partnerships and commercialization
- Product and market development
- Legal, operational, and regulatory execution
- Focused on moving federally supported research into scalable commercial adoption
The combination matters: RETINA required deep scientific invention. RetinaTek requires disciplined commercialization, claims control, clinical-development strategy, and market execution.
A platform company, starting with a focused wedge
RetinaTek is building a platform for objective neurocognitive measurement. The company's commercial focus is RT-TRACE for concussion recovery, with paid research and sponsored observational pilots available now under protocol. RetinaTek plans RT-Focus as its first 510(k) submission before pursuing condition-specific RT-TRACE claims after appropriate validation.
Research and clinical-development deployments
Objective neurocognitive endpoints, longitudinal protocols, usability studies, and validation work.
RT-TRACE concussion recovery
The focused commercial product being developed for objective longitudinal measurement in specialty concussion programs.
Staged regulatory path
A planned first 510(k) submission for RT-Focus, followed by condition-specific RT-TRACE development after appropriate validation.
Longitudinal measurement infrastructure
Repeatable, task-standardized data designed to support objective measurement of cognitive performance over time.
How RetinaTek operates
Evidence before claims
We distinguish published evidence, current product capabilities, and future regulated clinical claims.
Objective measurement over subjective guesswork
We build tools that measure cognitive performance, not just reported symptoms.
Repeatability matters
Brain health is dynamic. Measurement should support change over time.
Practical deployment
Useful cognitive assessment must fit real-world clinical, research, and commercial workflows.
Responsible commercialization
We are building revenue and adoption while maintaining clear claims boundaries.
Claims discipline
RETINA is an in-development neurocognitive measurement platform. RetinaTek has completed an FDA Q-Submission and plans RT-Focus as its first 510(k) submission. RT-TRACE remains investigational and is not FDA-cleared or FDA-approved for diagnosis, monitoring, treatment decisions, or return-to-activity decisions.
Work with RetinaTek
RetinaTek is engaging concussion programs, research teams, sponsors, clinical-development partners, strategic collaborators, and investors interested in objective longitudinal cognitive measurement.